Vaccitech PLC
F:2AB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Huhtamaki Oyj
OMXH:HUH1V
|
FI |
Vaccitech PLC
Income from Continuing Operations
Vaccitech PLC
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vaccitech PLC
F:2AB
|
Income from Continuing Operations
-$66.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Income from Continuing Operations
-$219m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Income from Continuing Operations
-£35.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Income from Continuing Operations
-$287.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Income from Continuing Operations
£47.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Income from Continuing Operations
-£30.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-9%
|
|
Vaccitech PLC
Glance View
Vaccitech Plc operates as a holding company. The company is headquartered in Oxford, Oxfordshire and currently employs 72 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The firm uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The firm has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).
See Also
What is Vaccitech PLC's Income from Continuing Operations?
Income from Continuing Operations
-66.5m
USD
Based on the financial report for Dec 31, 2025, Vaccitech PLC's Income from Continuing Operations amounts to -66.5m USD.
What is Vaccitech PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-30%
Over the last year, the Income from Continuing Operations growth was -9%.
